Advanced Solid Tumor trials recruiting in Ohio
All Advanced Solid Tumor trials nationally
19
Recruiting in Ohio
3
Cities with sites
Cities in Ohio
Cleveland 12Cincinnati 4Columbus 4
Recruiting trials in Ohio
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
- A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- A Study of DB-1310 in Advanced/Metastatic Solid Tumors
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- SW-682 in Advanced Solid Tumors
- Study of AVZO-021 in Patients With Advanced Solid Tumors
- Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
- Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
- Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)